{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:36:39Z","timestamp":1792449399024,"version":"4.5.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajo.2025.04.020","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:14:41Z","timestamp":1745435681000},"page":"556-569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Suprachoroidal Drug Delivery for VEGF Suppression in Wet AMD and Other Diseases With Choroidal Neovascularization"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-3059","authenticated-orcid":false,"given":"Bryce","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-2180","authenticated-orcid":false,"given":"Yooree Grace","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9076-8448","authenticated-orcid":false,"given":"Mark R.","family":"Prausnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajo.2025.04.020_bib0001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng","year":"2022","journal-title":"Genes Dis"},{"issue":"3","key":"10.1016\/j.ajo.2025.04.020_bib0002","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0008-4182(05)80074-2","article-title":"Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration","volume":"40","author":"Oliver-Fernandez","year":"2005","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2025.04.020_bib0003","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H","article-title":"Retinal and choroidal neovascularization","volume":"184","author":"Campochiaro","year":"2000","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.ajo.2025.04.020_bib0004","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archopht.1987.01060020063030","article-title":"Clinical characteristics of choroidal neovascular membranes","volume":"105","author":"Bressler","year":"1987","journal-title":"Arch Ophthalmol"},{"issue":"41","key":"10.1016\/j.ajo.2025.04.020_bib0005","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.2174\/1381612825666190206105943","article-title":"Pharmacotherapy for choroidal neovascularization due to uncommon causes","volume":"24","author":"Ho","year":"2018","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.020_bib0006","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/edrv-13-1-18","article-title":"Molecular and biological properties of the vascular endothelial growth factor family of proteins","volume":"13","author":"Ferrara","year":"1992","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ajo.2025.04.020_bib0007","doi-asserted-by":"crossref","unstructured":"Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr CCRev. 1997;18(1):4-25.","DOI":"10.1210\/edrv.18.1.0287"},{"issue":"44","key":"10.1016\/j.ajo.2025.04.020_bib0008","doi-asserted-by":"crossref","first-page":"18751","DOI":"10.1073\/pnas.0905010106","article-title":"An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris","volume":"106","author":"Saint-Geniez","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajo.2025.04.020_bib0009","first-page":"108","article-title":"VEGF production and signaling in Muller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases","volume":"139","author":"Le","year":"2017"},{"issue":"10","key":"10.1016\/j.ajo.2025.04.020_bib0010","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/IAE.0000000000002931","article-title":"Choroidal blood flow: review and potential explanation for the choroidal venous anatomy including the vortex vein system","volume":"40","author":"Spaide","year":"2020","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.ajo.2025.04.020_bib0011","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.ajpath.2019.04.005","article-title":"Choriocapillaris degeneration in geographic atrophy","volume":"189","author":"Sohn","year":"2019","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.ajo.2025.04.020_bib0012","doi-asserted-by":"crossref","first-page":"740","DOI":"10.18632\/aging.100078","article-title":"What determines the switch between atrophic and neovascular forms of age related macular degeneration? The role of BMP4 induced senescence","volume":"1","author":"Zhu","year":"2009","journal-title":"Aging (Albany NY)"},{"issue":"6","key":"10.1016\/j.ajo.2025.04.020_bib0013","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41591-020-0867-7","article-title":"Predicting conversion to wet age-related macular degeneration using deep learning","volume":"26","author":"Yim","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.020_bib0014","article-title":"Retinal and choroidal vascular abnormalities contribute to the conversion from dry to wet age-related macular degeneration: a theoretical approach","volume":"2","author":"Guidoboni","year":"2019","journal-title":"Proceedings of IMPRS"},{"issue":"11-12","key":"10.1016\/j.ajo.2025.04.020_bib0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2119\/molmed.2010.00070","article-title":"Endoplasmic reticulum stress in age-related macular degeneration: trigger for neovascularization","volume":"16","author":"Salminen","year":"2010","journal-title":"Mol Med"},{"issue":"7","key":"10.1016\/j.ajo.2025.04.020_bib0016","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00006982-200510000-00001","article-title":"VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis","volume":"25","author":"Gonzales","year":"2005","journal-title":"Retina"},{"issue":"14","key":"10.1016\/j.ajo.2025.04.020_bib0017","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajo.2025.04.020_bib0018","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"issue":"8","key":"10.1016\/j.ajo.2025.04.020_bib0019","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"Oncologist"},{"issue":"20","key":"10.1016\/j.ajo.2025.04.020_bib0020","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Group","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ajo.2025.04.020_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011230","article-title":"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration","volume":"9","author":"Moja","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.ajo.2025.04.020_bib0022","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2025.04.020_bib0023","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40123-021-00354-1","article-title":"A review of aflibercept treatment for macular disease","volume":"10","author":"Anguita","year":"2021","journal-title":"Ophthalmol Ther"},{"issue":"7","key":"10.1016\/j.ajo.2025.04.020_bib0024","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1167\/tvst.10.7.19","article-title":"Evaluation of long-lasting potential of suprachoroidal axitinib suspension via ocular and systemic disposition in rabbits","volume":"10","author":"Kansara","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ajo.2025.04.020_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119935","article-title":"Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularization","volume":"243","author":"Hackett","year":"2020","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.ajo.2025.04.020_bib0026","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1023\/A:1007517912927","article-title":"Permeability and diffusion in vitreous humor: implications for drug delivery","volume":"17","author":"Xu","year":"2000","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.ajo.2025.04.020_bib0027","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jconrel.2005.03.010","article-title":"Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant","volume":"105","author":"Park","year":"2005","journal-title":"J Control Release"},{"issue":"3-4","key":"10.1016\/j.ajo.2025.04.020_bib0028","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.drudis.2007.11.002","article-title":"Current and future ophthalmic drug delivery systems. A shift to the posterior segment","volume":"13","author":"Del Amo","year":"2008","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.ajo.2025.04.020_bib0029","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study","volume":"160","author":"Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.04.020_bib0030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","article-title":"The suprachoroidal space as a route of administration to the posterior segment of the eye","volume":"126","author":"Chiang","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.020_bib0031","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1167\/iovs.16-20377","article-title":"Thickness and closure kinetics of the suprachoroidal space following microneedle injection of liquid formulations","volume":"58","author":"Chiang","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.020_bib0032","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0420.1997.tb00245.x","article-title":"Corrosion casts of the suprachoroidal space and uveoscleral drainage routes in the human eye","volume":"75","author":"Krohn","year":"1997","journal-title":"Acta Ophthalmol Scand"},{"issue":"8","key":"10.1016\/j.ajo.2025.04.020_bib0033","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.020_bib0034","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.ajo.2025.04.020_bib0035","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17425247.2021.1867532","article-title":"Biomechanics of suprachoroidal drug delivery: from benchtop to clinical investigation in ocular therapies","volume":"18","author":"Hancock","year":"2021","journal-title":"Expert Opinion Drug Delivery"},{"issue":"6","key":"10.1016\/j.ajo.2025.04.020_bib0036","first-page":"459","article-title":"Suprachoroidal injection of triamcinolone acetonide suspension: ocular pharmacokinetics and distribution in rabbits demonstrates high and durable levels in the chorioretina","volume":"38","author":"Muya","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.ajo.2025.04.020_bib0037","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1167\/iovs.14-14651","article-title":"Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles","volume":"55","author":"Kim","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.04.020_bib0038","article-title":"Management of suprachoroidal hemorrhage during phacoemulsification: a comprehensive review","volume":"59","author":"Flores Marquez","year":"2023"},{"key":"10.1016\/j.ajo.2025.04.020_bib0039","first-page":"1879","article-title":"Outcomes of suprachoroidal haemorrhage drainage with and without vitrectomy: a 10-year study","volume":"35","author":"Qureshi","year":"2021"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.020_bib0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/1521-3900(200107)172:1<73::AID-MASY73>3.0.CO;2-R","article-title":"Treatment of intralocular diseases with poly(ortho ester)-based drug delivery systems","volume":"172","author":"Einmahl","year":"2001","journal-title":"Macromol Symposia"},{"issue":"5","key":"10.1016\/j.ajo.2025.04.020_bib0041","first-page":"1533","article-title":"Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye","volume":"43","author":"Einmahl","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2025.04.020_bib0042","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ajo.2006.05.045","article-title":"Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment","volume":"142","author":"Olsen","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.04.020_bib0043","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/IAE.0b013e3182278b0e","article-title":"Suprachoroidal drug infusion for the treatment of severe subfoveal hard exudates","volume":"32","author":"Rizzo","year":"2012","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajo.2025.04.020_bib0044","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000336045","article-title":"Safety of submacular suprachoroidal drug administration via a microcatheter: retrospective analysis of European treatment results","volume":"227","author":"Tetz","year":"2012","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ajo.2025.04.020_bib0045","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2147\/OPTH.S272506","article-title":"24-Month Efficacy of viscodilation of Schlemm\u2019s canal and the distal outflow system with iTrack ab-interno canaloplasty for the treatment of primary open-angle glaucoma","volume":"15","author":"Gallardo","year":"2021","journal-title":"Clin Ophthalmol"},{"issue":"15","key":"10.1016\/j.ajo.2025.04.020_bib0046","article-title":"Suprachoroidal microinjection of triamcinolone acetonide is well tolerated in the albino rabbit","volume":"54","author":"Verhoeven","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"15","key":"10.1016\/j.ajo.2025.04.020_bib0047","article-title":"Suprachoroidal microinjection delivers triamcinolone acetonide to therapeutically-relevant posterior ocular structures and limits exposure in the anterior segment","volume":"54","author":"Edelhauser","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"15","key":"10.1016\/j.ajo.2025.04.020_bib0048","article-title":"Evaluation of suprachoroidal microinjection of triamcinolone acetonide in a model of panuveitis in albino rabbits","volume":"54","author":"Patel","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ajo.2025.04.020_bib0049","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/tvst.12.3.31","article-title":"Suprachoroidal delivery in rats and guinea pigs using a high-precision microneedle injector","volume":"12","author":"Hejri","year":"2023","journal-title":"Transl Vis Sci Technol"},{"issue":"13-14","key":"10.1016\/j.ajo.2025.04.020_bib0050","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/hum.2020.281","article-title":"Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes","volume":"32","author":"Chung","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ajo.2025.04.020_bib0051","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates","volume":"16","author":"Yiu","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"10.1016\/j.ajo.2025.04.020_bib0052","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.13.10.14","article-title":"IOP reduction in nonhuman primates by microneedle injection of drug-free hydrogel to expand the suprachoroidal space","volume":"13","author":"Chung","year":"2024","journal-title":"Transl Vis Sci"},{"issue":"11","key":"10.1016\/j.ajo.2025.04.020_bib0053","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.9.11.27","article-title":"Clinical characterization of suprachoroidal injection procedure utilizing a microinjector across three retinal disorders","volume":"9","author":"Wan","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"7","key":"10.1016\/j.ajo.2025.04.020_bib0054","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.020_bib0055","first-page":"1209","article-title":"Safety of suprachoroidal injection procedure utilizing a microinjector across three retinal disorders","volume":"62","author":"Sharma","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.ajo.2025.04.020_bib0056","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jval.2022.07.008","article-title":"Suprachoroidal injection of triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis in the United States: a cost-effectiveness analysis","volume":"25","author":"Bhattacharyya","year":"2022","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.ajo.2025.04.020_bib0057","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/02713683.2016.1227448","article-title":"Subchoroidal release of VEGF and bFGF produces choroidal neovascularization in rabbit","volume":"42","author":"Wong","year":"2017","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ajo.2025.04.020_bib0058","first-page":"3924","article-title":"Bioengineering suprachoroidal pro-angiogenic VEGF\/bFGF implants for induction of subretinal neovascularization in the rabbit","volume":"44","author":"Ross-Cisneros","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.04.020_bib0059","first-page":"1374","article-title":"Both edema and leakage are expressed and are separable in long-term experimental CNV via sustained simultaneous release of VEGF and bFGF within the suprachoroidal space through transcleral implantation of a delivery device","volume":"49","author":"Rabin","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.04.020_bib0060","first-page":"2970","article-title":"Natural history of progressive experimental CNV in the rabbit after sustained release of both VEGF and bFGF within the supra-choroidal space","volume":"50","author":"Wong","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.04.020_bib0061","first-page":"1422","article-title":"Laser\u2013induced models of choroidal neovascularization in rabbits associated with sustained suprachoroidal and episcleral delivery of VEGF and bFGF","volume":"46","author":"Gum","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.04.020_bib0062","first-page":"4000","article-title":"Experimental CNV in cynomolgus monkeys after sustained release of VEGF and bFGF within the suprachoroidal space: part 2. natural history","volume":"52","author":"Wong","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.020_bib0063","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0002-9440(10)64525-7","article-title":"Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization","volume":"157","author":"Spilsbury","year":"2000","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.ajo.2025.04.020_bib0064","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.04.020_bib0065","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejpb.2021.10.003","article-title":"Suprachoroidal delivery of bevacizumab in rabbit in vivo eyes: rapid distribution throughout the posterior segment","volume":"169","author":"Sher","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"10.1016\/j.ajo.2025.04.020_bib0066","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1167\/iovs.16-21230","article-title":"A pharmacodynamic analysis of choroidal neovascularization in a porcine model using three targeted drugs","volume":"58","author":"Tran","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ajo.2025.04.020_bib0067","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1167\/iovs.10-6291","article-title":"Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model","volume":"52","author":"Olsen","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.04.020_bib0068","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejpb.2015.05.020","article-title":"Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles","volume":"95","author":"Kim","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ajo.2025.04.020_bib0069","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","article-title":"The suprachoroidal space as a route of administration to the posterior segment of the eye","volume":"126","author":"Chiang","year":"2018","journal-title":"Adv Drug Delivery Rev"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.020_bib0070","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1167\/iovs.16-20679","article-title":"Clearance kinetics and clearance routes of molecules from the suprachoroidal space after microneedle injection","volume":"58","author":"Chiang","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.ajo.2025.04.020_bib0071","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/adhm.201300696","article-title":"Particle-stabilized emulsion droplets for gravity-mediated targeting in the posterior segment of the eye","volume":"3","author":"Kim","year":"2014","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.ajo.2025.04.020_bib0072","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2018.03.001","article-title":"Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle","volume":"277","author":"Jung","year":"2018","journal-title":"J Control Release"},{"issue":"5","key":"10.1016\/j.ajo.2025.04.020_bib0073","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1167\/iovs.17-23758","article-title":"Targeted drug delivery in the suprachoroidal space by swollen hydrogel pushing","volume":"59","author":"Jung","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.ajo.2025.04.020_bib0074","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garcia-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.ajo.2025.04.020_bib0075","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3109\/02713683.2013.763988","article-title":"Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls","volume":"38","author":"Christoforidis","year":"2013","journal-title":"Curr Eye Res"},{"issue":"2","key":"10.1016\/j.ajo.2025.04.020_bib0076","article-title":"Drug-free, nonsurgical reduction of intraocular pressure for four months after suprachoroidal injection of hyaluronic acid hydrogel","volume":"8","author":"Chae","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.ajo.2025.04.020_bib0077","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.exer.2016.10.011","article-title":"Distribution of particles, small molecules and polymeric formulation excipients in the suprachoroidal space after microneedle injection","volume":"153","author":"Chiang","year":"2016","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajo.2025.04.020_bib0078","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2016.02.041","article-title":"Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma","volume":"228","author":"Chiang","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.ajo.2025.04.020_bib0079","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejpb.2021.10.003","article-title":"Suprachoroidal delivery of bevacizumab in rabbit in vivo eyes: rapid distribution throughout the posterior segment","volume":"169","author":"Sher","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ajo.2025.04.020_bib0080","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jconrel.2022.10.036","article-title":"Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space","volume":"352","author":"Jung","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.ajo.2025.04.020_bib0081","unstructured":"Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE\u2122 (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis, 2021. Accessed December 24, 2024. https:\/\/ir.clearsidebio.com\/news-releases\/news-release-details\/bausch-lomb-and-clearside-biomedical-announce-fda-approval."},{"issue":"4","key":"10.1016\/j.ajo.2025.04.020_bib0082","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0161-6420(02)01969-3","article-title":"Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection","volume":"110","author":"Beer","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.020_bib0083","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jconrel.2015.02.021","article-title":"Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model","volume":"203","author":"Chen","year":"2015","journal-title":"J Control Release"},{"issue":"8","key":"10.1016\/j.ajo.2025.04.020_bib0084","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/mp300716t","article-title":"Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab","volume":"10","author":"Tyagi","year":"2013","journal-title":"Mol Pharm"},{"issue":"13","key":"10.1016\/j.ajo.2025.04.020_bib0085","doi-asserted-by":"crossref","DOI":"10.3390\/polym14132593","article-title":"Bevacizumab-controlled delivery from polymeric microparticle systems as interesting tools for pathologic angiogenesis diseases","volume":"14","author":"De Negri Atanasio","year":"2022","journal-title":"Polymers (Basel)"},{"issue":"7","key":"10.1016\/j.ajo.2025.04.020_bib0086","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1021\/acs.molpharmaceut.0c00260","article-title":"Chitosan-polycaprolactone core-shell microparticles for sustained delivery of bevacizumab","volume":"17","author":"Jiang","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ajo.2025.04.020_bib0087","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.actbio.2018.07.040","article-title":"Nanoparticles provide long-term stability of bevacizumab preserving its antiangiogenic activity","volume":"78","author":"Sousa","year":"2018","journal-title":"Acta Biomater"},{"issue":"12","key":"10.1016\/j.ajo.2025.04.020_bib0088","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1021\/mp400487f","article-title":"Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab","volume":"10","author":"Yandrapu","year":"2013","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.ajo.2025.04.020_bib0089","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/ICU.0000000000000851","article-title":"Development of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"33","author":"Adamis","year":"2022","journal-title":"Curr Opin Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2025.04.020_bib0090","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1172\/JCI129085","article-title":"AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression","volume":"129","author":"Ding","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.020_bib0091","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1038\/s41467-024-48221-4","article-title":"An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species","volume":"15","author":"Luo","year":"2024","journal-title":"Nat Commun"},{"issue":"27","key":"10.1016\/j.ajo.2025.04.020_bib0092","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba1606","article-title":"Suprachoroidal gene transfer with nonviral nanoparticles","volume":"6","author":"Shen","year":"2020","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.020_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100586","article-title":"Safety and tolerability of suprachoroidal axitinib injectable suspension, for neovascular age-related macular degeneration; phase i\/iia open-label, dose-escalation trial","volume":"5","author":"Barakat","year":"2025","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.ajo.2025.04.020_bib0094","unstructured":"ODYSSEY phase 2b clinical trial results. 2024. Accessed December 21, 2024. https:\/\/ir.clearsidebio.com\/static-files\/6d0e1c10-c3b3-4fae-8d7e-ec995e825737."},{"key":"10.1016\/j.ajo.2025.04.020_bib0096","unstructured":"AsclepiX therapeutics completes enrollment in DISCOVER trial for neovascular age-related macular degeneration (nAMD). 2024. Accessed December 21, 2024. https:\/\/asclepix.com\/asclepix-therapeutics-completes-enrollment-in-discover-trial-for-neovascular-age-related-macular-degeneration-namd\/."},{"key":"10.1016\/j.ajo.2025.04.020_bib0097","first-page":"1497","article-title":"Suprachoroidal delivery of RGX-314 gene therapy for neovascular AMD: the phase II AAVIATE\u2122 study","volume":"63","author":"Khanani","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.04.020_bib0098","author":"Pitcher"},{"key":"10.1016\/j.ajo.2025.04.020_bib0099","unstructured":"REGENXBIO announces positive interim data from phase II AAVIATE\u00ae trial of ABBV-RGX-314 for the treatment of wet AMD using suprachoroidal delivery. 2024. Accessed December 21, 2024. https:\/\/ir.regenxbio.com\/news-releases\/news-release-details\/regenxbio-announces-positive-interim-data-phase-ii-aaviater."},{"key":"10.1016\/j.ajo.2025.04.020_bib0100","author":"Barakat"},{"key":"10.1016\/j.ajo.2025.04.020_bib0101","unstructured":"Shanghai BDgene Therapeutics Co, Ltd. Wet age-related macular degeneration (wAMD). Accessed December 21, 2024. https:\/\/www.bdgenetherapeutics.com\/en\/BD311.html."},{"key":"10.1016\/j.ajo.2025.04.020_bib0102","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1172\/JCI129085","article-title":"AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression","volume":"130","author":"Ding","year":"2019","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.ajo.2025.04.020_bib0103","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.1167\/iovs.17-23632","article-title":"Three-dimensional transport model for intravitreal and suprachoroidal drug injection","volume":"59","author":"Zhang","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.04.020_bib0104","series-title":"Tyrosine kinase inhibitors and retinal diseases: clinical studies","author":"Goldberg","year":"2024"},{"key":"10.1016\/j.ajo.2025.04.020_bib0105","series-title":"Two year results from the subretinal RGX-314 gene therapy phase 1\/2a study for the treatment of NAMD, and an update on suprachoroidal trials","author":"Avery","year":"2021"},{"key":"10.1016\/j.ajo.2025.04.020_bib0106","series-title":"Suprachoroidal delivery of investigational ABBV-RGX-314 for neovascular AMD: results from the phase II AAVIATE\u00ae study","author":"Boyer","year":"2023"},{"key":"10.1016\/j.ajo.2025.04.020_bib0107","unstructured":"London NJ. Suprachoroidal delivery of RGX-314 for neovascular AMD: initial results from the phase II AAVIATE\u00ae study. Retina Society Annual Meeting 2021. https:\/\/www.regenxbio.com\/getmedia\/4398cc62-0553-4db5-9c22-06b1feaddae3\/RGX-314_AAVIATE_data_Nik-London_Retina_Society_Oct-2021.pdf?ext=.pdf."},{"key":"10.1016\/j.ajo.2025.04.020_bib0108","unstructured":"Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD. 2024. Accessed December 21, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05210803?term=NCT05210803&rank=1#study-plan."},{"key":"10.1016\/j.ajo.2025.04.020_bib0109","unstructured":"Safety and tolerability of AL-001 Ophthalmic injection in subjects with WAMD. 2024. Accessed December 20, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06707753?term=NCT06707753&rank=1."},{"key":"10.1016\/j.ajo.2025.04.020_bib0110","unstructured":"Long-term follow-up study of AL-001 ophthalmic injection in subjects with WAMD. 2024. Accessed December 20, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06718816?term=NCT06718816&rank=1."},{"key":"10.1016\/j.ajo.2025.04.020_bib0111","unstructured":"VEGFA-targeting gene therapy to treat retinal and choroidal neovascularization diseases. 2022. Accessed December 30, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05099094?term=NCT05099094&rank=1#study-plan."}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425001965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425001965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T13:35:16Z","timestamp":1754919316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425001965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":110,"alternative-id":["S0002939425001965"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.04.020","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suprachoroidal Drug Delivery for VEGF Suppression in Wet AMD and Other Diseases With Choroidal Neovascularization","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}